Synlogic’s New Oral Form of Potential PKU Treatment, SYNB1618, Seen as Safe in Early Trial
News
Synlogic’s new solid oral formulation of its leading investigational candidate SYNB1618 for treating people with phenylketonuria (PKU) is safe in healthy volunteers, according to data from a bridging study. This positive ... Read more